<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00033722</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000069316</org_study_id>
    <secondary_id>TULA-T064031</secondary_id>
    <secondary_id>USO-01103</secondary_id>
    <nct_id>NCT00033722</nct_id>
  </id_info>
  <brief_title>Lometrexol Plus Folic Acid in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Phase II Multicenter Study Of Lometrexol Sodium And Folic Acid In Subjects With Previously Treated Stage IIIB or IV Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tularik</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Lometrexol may stop or slow the growth of tumor cells by blocking the enzymes&#xD;
      necessary for tumor cell growth. Folic acid may be effective in preventing or lessening the&#xD;
      side effects of lometrexol. Combining lometrexol with folic acid may be an effective&#xD;
      treatment for non-small cell lung cancer.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of combining lometrexol with folic acid in&#xD;
      treating patients who have stage IIIB or stage IV non-small cell lung cancer that has been&#xD;
      previously treated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the overall response rate in patients with previously treated stage IIIB or IV&#xD;
           non-small cell lung cancer when treated with lometrexol and folic acid.&#xD;
&#xD;
        -  Determine the complete response rate, duration of response, and time to progression in&#xD;
           patients treated with this regimen.&#xD;
&#xD;
        -  Determine the 1-year survival rate and overall survival in patients treated with this&#xD;
           regimen.&#xD;
&#xD;
        -  Determine the safety profile of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive oral folic acid once daily on days -7 to 6. Patients also receive lometrexol&#xD;
      IV over 30-60 seconds on day 1. Courses repeat every 21 days in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed up to 2 months after removal from study and then every 3 months&#xD;
      thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 50-100 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>February 2002</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Lung Cancer</condition>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>folic acid</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lometrexol</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed non-small cell lung cancer (NSCLC)&#xD;
&#xD;
               -  Stage IIIB or IV&#xD;
&#xD;
                    -  Squamous cell carcinoma&#xD;
&#xD;
                    -  Adenocarcinoma&#xD;
&#xD;
                    -  Large cell carcinoma&#xD;
&#xD;
                    -  Adenosquamous carcinoma&#xD;
&#xD;
          -  Progressive disease after receiving 1 cisplatin- or carboplatin-containing regimen for&#xD;
             stage IIIB or IV disease&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
               -  At least 1 lesion at least 1 cm x 1 cm by CT scan either not in a previously&#xD;
                  irradiated field or showing clear evidence of disease progression after radiation&#xD;
&#xD;
          -  No symptomatic or rapidly increasing, moderate or large amounts of pleural effusion or&#xD;
             ascites&#xD;
&#xD;
          -  No prior or concurrent CNS metastases (brain or meningeal)&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 70-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3*&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3*&#xD;
&#xD;
          -  Hemoglobin at least 9.0 g/dL*&#xD;
&#xD;
          -  *Without transfusions or growth factors in the previous 7 days&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN) (regardless of liver&#xD;
             involvement secondary to tumor)&#xD;
&#xD;
          -  AST and ALT no greater than 2.5 times ULN (5 times ULN if liver has tumor involvement)&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Calculated creatinine clearance at least 60 mL/min using Cockroft and Gault formula&#xD;
&#xD;
        Gastrointestinal:&#xD;
&#xD;
          -  No inflammatory bowel disease&#xD;
&#xD;
          -  No radiation enteritis&#xD;
&#xD;
          -  No malabsorption syndrome&#xD;
&#xD;
          -  No inability to absorb folic acid&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during study&#xD;
&#xD;
          -  No known untreated vitamin B12 deficiency&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No drug abusers&#xD;
&#xD;
          -  No prior malignancy within the past 5 years except adequately treated basal cell or&#xD;
             squamous cell skin cancer or carcinoma in situ of the cervix&#xD;
&#xD;
          -  No severe concurrent disease or major comorbidity that would preclude study&#xD;
             participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  At least 3 weeks since prior biologic therapy for NSCLC and recovered from acute side&#xD;
             effects&#xD;
&#xD;
          -  Prior treatment with an experimental vaccine allowed&#xD;
&#xD;
          -  No concurrent routine or prophylactic filgrastim (G-CSF), sargramostim (GM- CSF), or&#xD;
             epoetin alfa&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 3 weeks since prior chemotherapy for NSCLC (6 weeks for mitomycin or&#xD;
             nitrosourea) and recovered from acute side effects&#xD;
&#xD;
          -  Prior adjuvant or neoadjuvant chemotherapy allowed&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Recovered from acute side effects of prior radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy to 25% or more of bone marrow&#xD;
&#xD;
          -  No prior whole pelvic irradiation&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  At least 3 weeks since prior major surgery and recovered&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  At least 3 weeks since prior investigational agent&#xD;
&#xD;
          -  No concurrent proguanil, trimethoprim, co-trimoxazole, or pyrimethamine&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Tesarowski</last_name>
    <role>Study Chair</role>
    <affiliation>Tularik</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF Cancer Center and Cancer Research Institute</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143-0128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Centers of Florida (U.S. Oncology)</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louisiana State University School of Medicine</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112-2822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US Oncology - Albany Regional Cancer Center</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.S. Oncology Research Inc.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tyler Cancer Center</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Northwest</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2002</verification_date>
  <study_first_submitted>April 9, 2002</study_first_submitted>
  <study_first_submitted_qc>August 5, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2003</study_first_posted>
  <last_update_submitted>January 3, 2014</last_update_submitted>
  <last_update_submitted_qc>January 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 6, 2014</last_update_posted>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <keyword>squamous cell lung cancer</keyword>
  <keyword>large cell lung cancer</keyword>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <keyword>adenocarcinoma of the lung</keyword>
  <keyword>adenosquamous cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Lometrexol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

